[go: up one dir, main page]

DK3655038T3 - Farmaceutisk sammensætning - Google Patents

Farmaceutisk sammensætning Download PDF

Info

Publication number
DK3655038T3
DK3655038T3 DK18746859.0T DK18746859T DK3655038T3 DK 3655038 T3 DK3655038 T3 DK 3655038T3 DK 18746859 T DK18746859 T DK 18746859T DK 3655038 T3 DK3655038 T3 DK 3655038T3
Authority
DK
Denmark
Prior art keywords
pharmaceutical composition
pharmaceutical
composition
Prior art date
Application number
DK18746859.0T
Other languages
English (en)
Inventor
Christophe Roberge
Anthony Rech
Jean-Manuel Cros
Myriam Abbassi
Lea Pebrel
Audrey Petit
Juliette Serindoux
Adolfo López-Noriega
Original Assignee
Medincell S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medincell S A filed Critical Medincell S A
Application granted granted Critical
Publication of DK3655038T3 publication Critical patent/DK3655038T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0029—Parenteral nutrition; Parenteral nutrition compositions as drug carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A61K9/204—Polyesters, e.g. poly(lactide-co-glycolide)
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G63/00—Macromolecular compounds obtained by reactions forming a carboxylic ester link in the main chain of the macromolecule
    • C08G63/66—Polyesters containing oxygen in the form of ether groups
    • C08G63/664—Polyesters containing oxygen in the form of ether groups derived from hydroxy carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L67/00—Compositions of polyesters obtained by reactions forming a carboxylic ester link in the main chain; Compositions of derivatives of such polymers
    • C08L67/04—Polyesters derived from hydroxycarboxylic acids, e.g. lactones
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L71/00—Compositions of polyethers obtained by reactions forming an ether link in the main chain; Compositions of derivatives of such polymers
    • C08L71/02—Polyalkylene oxides
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L2203/00—Applications
    • C08L2203/02—Applications for biomedical use
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L2205/00—Polymer mixtures characterised by other features
    • C08L2205/02—Polymer mixtures characterised by other features containing two or more polymers of the same C08L -group
    • C08L2205/025—Polymer mixtures characterised by other features containing two or more polymers of the same C08L -group containing two or more polymers of the same hierarchy C08L, and differing only in parameters such as density, comonomer content, molecular weight, structure
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L2205/00—Polymer mixtures characterised by other features
    • C08L2205/03—Polymer mixtures characterised by other features containing three or more polymers in a blend

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Polymers & Plastics (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK18746859.0T 2017-07-17 2018-07-17 Farmaceutisk sammensætning DK3655038T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762533370P 2017-07-17 2017-07-17
PCT/EP2018/069442 WO2019016236A1 (en) 2017-07-17 2018-07-17 PHARMACEUTICAL COMPOSITION

Publications (1)

Publication Number Publication Date
DK3655038T3 true DK3655038T3 (da) 2025-02-17

Family

ID=63047314

Family Applications (2)

Application Number Title Priority Date Filing Date
DK18746859.0T DK3655038T3 (da) 2017-07-17 2018-07-17 Farmaceutisk sammensætning
DK18759254.8T DK3655017T3 (da) 2017-07-17 2018-07-17 Farmaceutisk sammensætning

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK18759254.8T DK3655017T3 (da) 2017-07-17 2018-07-17 Farmaceutisk sammensætning

Country Status (25)

Country Link
US (3) US11612563B2 (da)
EP (4) EP4574906A3 (da)
JP (3) JP7210816B6 (da)
KR (1) KR102745079B1 (da)
CN (1) CN111107840A (da)
AR (3) AR113097A1 (da)
AU (1) AU2018304881B2 (da)
BR (1) BR112020001031A2 (da)
CA (1) CA3069787A1 (da)
DK (2) DK3655038T3 (da)
EA (1) EA202090161A1 (da)
ES (2) ES3010399T3 (da)
FI (2) FI3655017T3 (da)
HR (2) HRP20250087T1 (da)
HU (2) HUE070046T2 (da)
IL (1) IL271986B2 (da)
LT (2) LT3655017T (da)
MX (1) MX2020000618A (da)
PL (2) PL3655038T3 (da)
PT (2) PT3655038T (da)
RS (1) RS66643B1 (da)
SI (2) SI3655017T1 (da)
SM (1) SMT202500130T1 (da)
TW (3) TWI795423B (da)
WO (3) WO2019016233A1 (da)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3655017T1 (sl) * 2017-07-17 2025-06-30 Medincell S.A. Farmacevtski sestavki
GB201900258D0 (en) 2019-01-08 2019-02-27 Medincell Pharmaceutical composition
US11680107B2 (en) 2019-03-22 2023-06-20 Taipei Medical University Hydrogel composition for drug delivery and uses thereof
EP4027973B8 (en) 2019-09-13 2025-12-17 Medincell S.A. Drug delivery formulations
EP4100002A4 (en) * 2020-01-10 2024-09-25 Equilibre Biopharmaceuticals BV TREATMENT OF NEUROLOGICAL DISORDERS WITH AVERMECTINS
GB202010340D0 (en) * 2020-07-06 2020-08-19 Medincell Pharmaceutical composition
EP4014963A1 (en) * 2020-12-16 2022-06-22 Medincell Pharmaceutical composition
WO2022129417A1 (en) * 2020-12-16 2022-06-23 Medincell Methods and compositions for the prophylactic treatment of sars-cov-2 virus (covid-19)
GB202104224D0 (en) * 2021-03-25 2021-05-12 Medincell Pharmaceutical composition
AU2022264844A1 (en) * 2021-04-30 2023-11-23 Medincell Sa New formulation
CN118159252A (zh) 2021-08-05 2024-06-07 美蒂森股份公司 药物组合物
AU2024208071A1 (en) * 2023-01-10 2025-06-12 Medincell Sa Olanzapine compositions and methods of use
WO2025104289A1 (en) 2023-11-17 2025-05-22 Medincell S.A. Antineoplastic combinations
WO2025224317A1 (en) * 2024-04-25 2025-10-30 Medincell S.A. A method for targeting pharmaceutically active principle in total knee replacement

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL113359A (en) 1995-04-13 1999-06-20 Univ Ben Gurion Polysaccharide drug delivery matrix and slow release pharmaceutical preparation containing it
FR2741628B1 (fr) 1995-11-29 1998-02-06 Centre Nat Rech Scient Nouveaux hydrogels a base de copolymeres trisequences et leur application notamment a la liberation progressive de principes actifs
EP1024790A4 (en) 1997-08-08 2000-10-25 Univ Utah Res Found INJECTABLE BIODEGRADABLE BLOCK COPOLYMER GELS FOR USE IN DRUG ADMINISTRATION
US20020164374A1 (en) 1997-10-29 2002-11-07 John Jackson Polymeric systems for drug delivery and uses thereof
US6541033B1 (en) 1998-06-30 2003-04-01 Amgen Inc. Thermosensitive biodegradable hydrogels for sustained delivery of leptin
KR100416242B1 (ko) 1999-12-22 2004-01-31 주식회사 삼양사 약물전달체용 생분해성 블록 공중합체의 액체 조성물 및이의 제조방법
US7018645B1 (en) 2000-04-27 2006-03-28 Macromed, Inc. Mixtures of various triblock polyester polyethylene glycol copolymers having improved gel properties
US20020192286A1 (en) 2001-03-27 2002-12-19 Macromed, Incorporated Biodegradable triblock copolymers as solubilizing agents for drugs and method of use thereof
IL151288A0 (en) 2001-08-27 2003-04-10 Yissum Res Dev Co Multi-component reverse thermo-sensitive polymeric systems
US6592899B2 (en) 2001-10-03 2003-07-15 Macromed Incorporated PLA/PLGA oligomers combined with block copolymers for enhancing solubility of a drug in water
US20030228366A1 (en) 2002-06-11 2003-12-11 Chung Shih Reconstitutable compositions of biodegradable block copolymers
US7649023B2 (en) * 2002-06-11 2010-01-19 Novartis Ag Biodegradable block copolymeric compositions for drug delivery
US20060034889A1 (en) 2004-08-16 2006-02-16 Macromed, Inc. Biodegradable diblock copolymers having reverse thermal gelation properties and methods of use thereof
US20060046961A1 (en) 2004-09-02 2006-03-02 Mckay William F Controlled and directed local delivery of anti-inflammatory compositions
WO2007019439A2 (en) 2005-08-04 2007-02-15 Angiotech International Ag Block copolymer compositions and uses thereof
ATE458773T1 (de) 2006-03-09 2010-03-15 Coloplast As Abbaubare copolymere mit einem hydrophilen block mit verbesserter biokompatibilität für die weichgeweberegeneration
JP5410434B2 (ja) 2007-09-28 2014-02-05 バインド セラピューティックス インコーポレイテッド ナノ粒子を用いた癌細胞の標的化
ES2324009B1 (es) 2007-11-23 2010-05-21 Gp Pharm S.A. Composicion farmaceutica de liberacion sostenida de somatostatina o un analogo suyo.
TWI388591B (zh) * 2008-03-28 2013-03-11 Ind Tech Res Inst 溫度敏感性材料
US7993666B2 (en) 2008-04-18 2011-08-09 Warsaw Orthopedic, Inc. Methods and compositions for treating pain comprising a statin
US8956636B2 (en) 2008-04-18 2015-02-17 Warsaw Orthopedic, Inc. Methods and compositions for treating postoperative pain comprosing ketorolac
DK2774608T3 (da) 2008-06-16 2020-01-13 Pfizer Lægemiddelladede polymere nanopartikler og fremgangsmåder til fremstilling og anvendelse deraf
US20100015049A1 (en) 2008-07-16 2010-01-21 Warsaw Orthopedic, Inc. Methods and compositions for treating postoperative pain comprising nonsteroidal anti-inflammatory agents
US20110097375A1 (en) 2009-10-26 2011-04-28 Warsaw Orthopedic, Inc. Formulation for preventing or reducing bleeding at a surgical site
WO2011084518A2 (en) 2009-12-15 2011-07-14 Bind Biosciences, Inc. Therapeutic polymeric nanoparticles comprising corticosteroids and methods of making and using same
EP2515946B1 (en) 2009-12-23 2019-05-22 The Board of Trustees of the University of Illionis Nanoconjugates and nanoconjugate formulations
US20110319473A1 (en) 2010-06-29 2011-12-29 Surmodics, Inc. Compositions and methods for enhancement of nucleic acid delivery
AU2011350898B2 (en) 2010-12-29 2016-09-08 Medincell Biodegradable drug delivery compositions
CN102058909A (zh) 2011-01-18 2011-05-18 复旦大学 聚乙二醇－共聚酯嵌段共聚物防粘连材料及其制备方法与应用
AU2012237260A1 (en) * 2011-03-31 2013-11-14 Ingell Technologies Holding B.V. Biodegradable compositions suitable for controlled release
CA2831471C (en) * 2011-03-31 2020-02-25 Ingell Technologies Holding B.V. Biodegradable compositions suitable for controlled release
EP2674167A1 (en) 2012-06-14 2013-12-18 PLS-Design GmbH Controlled activation of complement components for use as endogenous adjuvant
MX353280B (es) 2012-06-27 2018-01-05 Medincell Suministro de farmaco biodegradable para las composiciones hidrofobicas.
US8954932B2 (en) * 2012-12-11 2015-02-10 International Business Machines Corporation Crash notification between debuggers
WO2014165923A1 (en) 2013-04-11 2014-10-16 Commonwealth Scientific And Industrial Research Organisation Composition for controlled delivery of bioactive agents
KR101512759B1 (ko) * 2013-08-30 2015-04-16 아주대학교산학협력단 이온성 작용기가 곁사슬 또는 말단에 도입된 온도감응성 폴리에틸렌글리콜/폴리에스터 블록 공중합체 및 이의 제조방법
CN103601878B (zh) * 2013-11-25 2015-05-13 沈阳药科大学 高稳定性聚乙二醇-聚酯聚合物及其应用
EP2918262B1 (en) 2014-03-10 2023-08-09 PLS-Design GmbH Induction of antigen-specific tolerance by peripheral phagocytosis
JP2017513950A (ja) 2014-04-18 2017-06-01 ファイザー・インク Ｋ−ｒａｓ変異を有するがんを処置するためのドセタキセルを含むナノ粒子
WO2016172042A1 (en) 2015-04-18 2016-10-27 The Texas A&M University System Polymer systems and their applications in diagnostics and drug delivery
EP3095440B1 (en) 2015-05-19 2020-01-15 PLS-Design GmbH Antigen-specific immunotherapy using tolerizing liposomes
WO2017044936A1 (en) 2015-09-11 2017-03-16 Pfizer Inc. Methods of controlling morphology of polymeric nanoparticles
AU2016355236C1 (en) * 2015-11-16 2022-09-22 Medincell A method for morselizing and/or targeting pharmaceutically active principles to synovial tissue
US20170266187A1 (en) 2016-03-15 2017-09-21 Pfizer Inc. Pemetrexed Polymeric Nanoparticles And Methods Of Making And Using Same
CN105963257B (zh) 2016-04-26 2021-01-22 广州帝奇医药技术有限公司 一种缓释微粒的制备方法
CN105878174B (zh) 2016-04-26 2021-06-29 广州帝奇医药技术有限公司 一种固体分散体及其制备方法与应用
CN105963258B (zh) 2016-04-26 2021-01-22 广州帝奇医药技术有限公司 一种缓释微粒的制备方法
CN105878191B (zh) 2016-04-26 2021-01-22 广州帝奇医药技术有限公司 缓释微粒的制备方法、制得的缓释微粒及其应用
EP3503877B8 (en) 2016-08-26 2022-04-20 SK Joint Ventures II, LLC Biodegradable polymer formulations for extended efficacy of botulinum toxin
SI3655017T1 (sl) * 2017-07-17 2025-06-30 Medincell S.A. Farmacevtski sestavki

Also Published As

Publication number Publication date
JP2020527590A (ja) 2020-09-10
US11612563B2 (en) 2023-03-28
TW201907955A (zh) 2019-03-01
JP7210816B2 (ja) 2023-01-24
TWI795422B (zh) 2023-03-11
KR102745079B1 (ko) 2024-12-24
TWI795423B (zh) 2023-03-11
CN111107840A (zh) 2020-05-05
WO2019016236A1 (en) 2019-01-24
SI3655038T1 (sl) 2025-05-30
PT3655017T (pt) 2025-03-26
FI3655017T3 (fi) 2025-03-27
SI3655017T1 (sl) 2025-06-30
ES3010399T3 (en) 2025-04-02
US20200171157A1 (en) 2020-06-04
IL271986B1 (en) 2023-04-01
HRP20250339T1 (hr) 2025-05-09
AR113248A1 (es) 2020-03-11
JP2020527587A (ja) 2020-09-10
EA202090161A1 (ru) 2020-06-29
IL271986A (en) 2020-02-27
AR113097A1 (es) 2020-01-29
TWI795421B (zh) 2023-03-11
WO2019016233A1 (en) 2019-01-24
JP7187738B2 (ja) 2022-12-13
CA3069787A1 (en) 2019-01-24
US20200179518A1 (en) 2020-06-11
HUE070046T2 (hu) 2025-05-28
JP7205019B2 (ja) 2023-01-17
LT3655038T (lt) 2025-02-10
BR112020001031A2 (pt) 2020-07-14
JP2020527586A (ja) 2020-09-10
JP7210816B6 (ja) 2023-02-03
US11801217B2 (en) 2023-10-31
MX2020000618A (es) 2020-09-28
AR113096A1 (es) 2020-01-29
PT3655038T (pt) 2025-02-04
TW201907954A (zh) 2019-03-01
TW201907956A (zh) 2019-03-01
EP3655038A1 (en) 2020-05-27
FI3655038T3 (fi) 2025-02-11
EP3655037A1 (en) 2020-05-27
PL3655038T3 (pl) 2025-04-22
LT3655017T (lt) 2025-04-10
US20200163873A1 (en) 2020-05-28
SMT202500130T1 (it) 2025-05-12
EP4574906A2 (en) 2025-06-25
EP3655017A1 (en) 2020-05-27
HUE070940T2 (hu) 2025-07-28
WO2019016234A1 (en) 2019-01-24
PL3655017T3 (pl) 2025-06-09
US11666527B2 (en) 2023-06-06
RS66643B1 (sr) 2025-04-30
EP4574906A3 (en) 2025-09-10
KR20200032719A (ko) 2020-03-26
EP3655038B1 (en) 2024-12-18
DK3655017T3 (da) 2025-03-31
EP3655017B1 (en) 2025-01-22
HRP20250087T1 (hr) 2025-03-28
EP3655037B1 (en) 2025-01-22
IL271986B2 (en) 2023-08-01
AU2018304881A1 (en) 2020-01-30
AU2018304881B2 (en) 2024-06-20
ES3015765T3 (en) 2025-05-07
JP7205019B6 (ja) 2023-02-03

Similar Documents

Publication Publication Date Title
EP3722358A4 (en) COMPOSITION
DK3697376T3 (da) Sammensætning
EP3513809A4 (en) MEDICAL COMPOSITION
DK3529248T3 (da) Farmaceutiske sammensætninger
EP3493799A4 (en) CANNABIS
DK3655038T3 (da) Farmaceutisk sammensætning
DK3256138T3 (da) Farmaceutiske sammensætninger omfattende meloxicam
EP3641771A4 (en) PHARMACEUTICAL COMPOSITIONS
EP3493798A4 (en) CANNABIS
EP3454899C0 (en) PHARMACEUTICAL COMPOSITION
DK3634377T3 (da) Farmaceutisk formulering
EP3603642A4 (en) PHARMACEUTICAL PREPARATION
DK3583943T3 (da) Farmaceutisk sammensætning
MA49837A (fr) Compositions pharmaceutiques
EP3646866A4 (en) PHARMACEUTICAL PREPARATION
SMT202400478T1 (it) Composizione farmaceutica
DK3728220T3 (da) Farmaceutiske forbindelser
DK3313370T3 (da) Oftalmologisk farmaceutisk sammensætning
EP3646863A4 (en) PHARMACEUTICAL COMPOSITION
DK3288933T3 (da) Oxindolforbindelser og farmaceutiske sammensætninger deraf
EP3727485C0 (en) PHARMACEUTICAL COMPOSITION
EP3675653C0 (fr) Composition antimycotoxine
EP3646865A4 (en) MEDICINE
DK3601277T3 (da) Farmaceutisk formulering
DK3089740T3 (da) Farmaceutisk sammensætning